Cite
HARVARD Citation
Goldman, J. et al. (2021). Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet oncology. 22 (1), pp. 51-65. [Online].